RAPP · Rapport Therapeutics, Inc.
$47.42
+0.06 (+0.13%)
At close · Aug 14
Market Cap
$2.28B
Shares
47.98M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$47.42
Open$47.00
Day$46.37–47.64
52W close$14.24–48.82
Avg vol 30d350K
Short int2.2M · 4.7% float · 7.5d
Short vol53%
Last earningsAug 5, 2026
DataJun 2024–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+43%
above
Price vs 50-day avg
+16%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
96%
near high
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+57%
trailing
YTD return
+56%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.69% of float · ▼ -16.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
159 holders — near 2-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
+24%
Y/Y
Free cash flow
$-88.1M
Balance sheet
$52.6M
net cash
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+43%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
96%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $41 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.69% of float · ▼ -16.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
159 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $47 · 96%
Range high $49
vs 200-day avg +43%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RAPP
this stock
Rapport Therapeutics, Inc.
|
$2.28B | +56.3% | — | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RAPP | +4.2% | +11.3% | +57.4% | +15.7% | +56.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +3.8% | +6.8% | +43.7% | +11.8% | +42.5% |
Key facts
CIK
2012593
CUSIP
75383L102
13F (30d)
156 filings
153 filers
Visit website
Investor relations